

# Dominic Theuns, Fehra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4866427/publications.pdf>

Version: 2024-02-01

98  
papers

4,711  
citations

147801

31  
h-index

98798

67  
g-index

98  
all docs

98  
docs citations

98  
times ranked

3323  
citing authors

#	ARTICLE	IF	CITATIONS
1	An Entirely Subcutaneous Implantable Cardioverter-Defibrillator. <i>New England Journal of Medicine</i> , 2010, 363, 36-44.	27.0	686
2	Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1605-1615.	2.8	458
3	Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. <i>European Heart Journal</i> , 2014, 35, 1657-1665.	2.2	410
4	Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry. <i>Journal of the American College of Cardiology</i> , 2017, 70, 830-841.	2.8	266
5	The Entirely Subcutaneous Implantable Cardioverter-Defibrillator. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1933-1939.	2.8	205
6	Prevention of inappropriate therapy in implantable cardioverter-defibrillators. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2362-2367.	2.8	145
7	Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. <i>Europace</i> , 2010, 12, 1564-1570.	1.7	142
8	Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. <i>Circulation</i> , 2021, 143, 7-17.	1.6	132
9	Prospective blinded evaluation of a novel sensing methodology designed to reduce inappropriate shocks by the subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2018, 15, 1515-1522.	0.7	123
10	Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management. <i>International Journal of Cardiology</i> , 2015, 195, 126-133.	1.7	120
11	Validation of the 2014 European Society of Cardiology Guidelines Risk Prediction Model for the Primary Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 829-835.	4.8	113
12	The learning curve associated with the introduction of the subcutaneous implantable defibrillator. <i>Europace</i> , 2016, 18, 1010-1015.	1.7	95
13	Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. <i>Heart Rhythm</i> , 2016, 13, 1066-1074.	0.7	92
14	Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. <i>Heart Rhythm</i> , 2014, 11, 1352-1358.	0.7	86
15	Prevention of inappropriate therapy in implantable defibrillators: A meta-analysis of clinical trials comparing single-chamber and dual-chamber arrhythmia discrimination algorithms. <i>International Journal of Cardiology</i> , 2008, 125, 352-357.	1.7	77
16	The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. <i>Europace</i> , 2011, 13, 62-69.	1.7	77
17	Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. <i>Heart Rhythm</i> , 2016, 13, 157-164.	0.7	67
18	Risk of chronic anxiety in implantable defibrillator patients: A multi-center study. <i>International Journal of Cardiology</i> , 2011, 147, 420-423.	1.7	59

#	ARTICLE	IF	CITATIONS
19	Course of anxiety and device-related concerns in implantable cardioverter defibrillator patients the first year post implantation. <i>Europace</i> , 2010, 12, 1119-1126.	1.7	57
20	Prevalence and Presentation of Externalized Conductors and Electrical Abnormalities in Riata Defibrillator Leads After Fluoroscopic Screening. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 1059-1063.	4.8	49
21	Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. <i>European Heart Journal</i> , 2022, 43, 2037-2050.	2.2	47
22	A prospective study on safety of catheter ablation procedures: Contact force guided ablation could reduce the risk of cardiac perforation. <i>International Journal of Cardiology</i> , 2015, 179, 441-448.	1.7	44
23	Clinical variables predicting inappropriate use of implantable cardioverter-defibrillator in patients with coronary heart disease or nonischemic dilated cardiomyopathy. <i>American Journal of Cardiology</i> , 2005, 95, 271-274.	1.6	43
24	Evaluation of FactORs Impacting CLinical Outcome and Cost EffectiveneSS of the Sâ€CD: Design and Rationale of the EFFORTLESS Sâ€CD Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 574-579.	1.2	42
25	Longevity of implantable cardioverter defibrillators: a comparison among manufacturers and over time. <i>Europace</i> , 2016, 18, 710-717.	1.7	41
26	Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2017, 119, 100-105.	1.6	40
27	Sixâ€year followâ€up of the initial Dutch subcutaneous implantable cardioverterâ€defibrillator cohort: Longâ€term complications, replacements, and battery longevity. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1010-1016.	1.7	39
28	Ventricular Tachyarrhythmias and Mortality in Patients With an Implantable Cardioverter Defibrillator. <i>Psychosomatic Medicine</i> , 2014, 76, 58-65.	2.0	38
29	Atrial fibrillation reduction by renal sympathetic denervation: 12 monthsâ€™ results of the AFFORD study. <i>Clinical Research in Cardiology</i> , 2019, 108, 634-642.	3.3	38
30	Longevity of the Subcutaneous Implantable Defibrillator. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1159-1163.	4.8	37
31	Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapyâ€defibrillator patients. <i>European Journal of Heart Failure</i> , 2010, 12, 1325-1332.	7.1	35
32	Ice mapping during cryothermal ablation of accessory pathways in WPW: the role of the temperature time constant. <i>Europace</i> , 2004, 6, 116-122.	1.7	32
33	Analysis of 57,148 Transmissions by Remote Monitoring of Implantable Cardioverter Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, S63-S65.	1.2	32
34	Comorbidity burden is associated with poor psychological well-being and physical health status in patients with an implantable cardioverter-defibrillator. <i>Europace</i> , 2013, 15, 1468-1474.	1.7	31
35	Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. <i>Heart</i> , 2014, 100, 1188-1192.	2.9	31
36	Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. <i>Heart Rhythm</i> , 2017, 14, 367-375.	0.7	30

#	ARTICLE	IF	CITATIONS
37	Insertable cardiac monitors: current indications and devices. Expert Review of Medical Devices, 2019, 16, 45-55.	2.8	30
38	A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable Defibrillator System Versus a Transvenous System (from the EFFORTLESS S-ICD Quality of Life) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 69	0.7	10
39	Defibrillation efficacy testing: Long-term follow-up and mortality. Europace, 2005, 7, 509-515.	1.7	26
40	Evaluation of morphology discrimination for ventricular tachycardia diagnosis in implantable cardioverter-defibrillators. Heart Rhythm, 2006, 3, 1332-1338.	0.7	26
41	Evaluation of subcutaneous implantable cardioverter-defibrillator performance in patients with ion channelopathies from the EFFORTLESS cohort and comparison with a meta-analysis of transvenous ICD outcomes. Heart Rhythm O2, 2020, 1, 326-335.	1.7	26
42	Morphology discrimination in implantable cardioverter-defibrillators: consistency of template match percentage during atrial tachyarrhythmias at different heart rates. Europace, 2008, 10, 1060-1066.	1.7	25
43	Shock and Patient Preimplantation Type D Personality Are Associated With Poor Health Status in Patients With Implantable Cardioverter-Defibrillator. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 373-380.	2.2	25
44	Remote monitoring of heart failure: benefits for therapeutic decision making. Expert Review of Cardiovascular Therapy, 2017, 15, 503-515.	1.5	23
45	Increased risk of ventricular arrhythmias in survivors of out-of-hospital cardiac arrest with chronic total coronary occlusion. Heart Rhythm, 2018, 15, 124-129.	0.7	22
46	Emerging electromagnetic interferences between implantable cardioverter-defibrillators and left ventricular assist devices. Europace, 2020, 22, 584-587.	1.7	22
47	Web-based distress management for implantable cardioverter defibrillator patients: A randomized controlled trial.. Health Psychology, 2017, 36, 392-401.	1.6	21
48	Poor health status and distress in cardiac patients: the role of device therapy vs. underlying heart disease. Europace, 2013, 15, 355-361.	1.7	20
49	Development and external validation of prediction models to predict implantable cardioverter-defibrillator efficacy in primary prevention of sudden cardiac death. Europace, 2021, 23, 887-897.	1.7	19
50	Comparative study of the failure rates among 3 implantable defibrillator leads. Heart Rhythm, 2016, 13, 2299-2305.	0.7	16
51	Non-sustained ventricular tachycardia in patients with congenital heart disease: An important sign?. International Journal of Cardiology, 2016, 206, 158-163.	1.7	15
52	Value of implantable loop recorders in patients with structural or electrical heart disease. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 203-208.	1.3	15
53	Evaluation of a novel automatic screening tool for determining eligibility for a subcutaneous implantable cardioverter-defibrillator. International Journal of Cardiology, 2018, 272, 97-101.	1.7	15
54	Psychological distress in patients with an implantable cardioverter defibrillator and their partners. Journal of Psychosomatic Research, 2018, 113, 16-21.	2.6	15

#	ARTICLE	IF	CITATIONS
55	Air entrapment causing early inappropriate shocks in a patient with a subcutaneous cardioverter-defibrillator. <i>HeartRhythm Case Reports</i> , 2015, 1, 156-158.	0.4	14
56	Outcome in patients with an ICD incorporating cardiac resynchronisation therapy: Differences between primary and secondary prophylaxis. <i>European Journal of Heart Failure</i> , 2005, 7, 1027-1032.	7.1	13
57	Early detection of ventricular arrhythmias in adults with congenital heart disease using an insertable cardiac monitor (EDVA-CHD study). <i>International Journal of Cardiology</i> , 2020, 305, 63-69.	1.7	13
58	Clinical Update of the Latest Evidence for CardioMEMS Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Promising System for Remote Heart Failure Care. <i>Sensors</i> , 2021, 21, 2335.	3.8	13
59	Type and rate of atrial fibrillation termination due to rotational activity ablation combined with pulmonary vein isolation. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 862-869.	1.7	12
60	Information provision, satisfaction and emotional distress in patients with an implantable cardioverter-defibrillator. <i>International Journal of Cardiology</i> , 2014, 177, 586-588.	1.7	11
61	Trajectories of Patient-Reported Health Status in Patients With an Implantable Cardioverter Defibrillator. <i>American Journal of Cardiology</i> , 2015, 115, 771-777.	1.6	11
62	Conduction dynamics after transcatheter aortic valve implantation and implications for permanent pacemaker implantation and early discharge: the CONDUCT-study. <i>Europace</i> , 2018, 20, 1981-1988.	1.7	11
63	Quality of life, depression, and anxiety in patients with a subcutaneous versus transvenous defibrillator system. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 1541-1551.	1.2	11
64	Anxiety, depression, ventricular arrhythmias and mortality in patients with an implantable cardioverter defibrillator: 7Âyears' follow-up of the MIDAS cohort. <i>General Hospital Psychiatry</i> , 2020, 66, 154-160.	2.4	11
65	Outcome of Insertable Cardiac Monitors in Symptomatic Patients with Brugada Syndrome at Low Risk of Sudden Cardiac Death. <i>Cardiology</i> , 2020, 145, 413-420.	1.4	11
66	Prognostic Role of Highâ€Sensitivity Câ€Reactive Protein and Bâ€Type Natriuretic Peptide in Implantable Cardioverterâ€Defibrillator Patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 275-282.	1.2	10
67	Remote Monitoring of Heart Failure in Patients with Implantable Cardioverter-Defibrillators: Current Status and Future Needs. <i>Sensors</i> , 2021, 21, 3763.	3.8	10
68	Procedural and long-term outcome after catheter ablation of idiopathic outflow tract ventricular arrhythmias: comparing manual, contact force, and magnetic navigated ablation. <i>Europace</i> , 2018, 20, ii22-ii27.	1.7	9
69	Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices recipients: a consensus document from the European Association of Preventive Cardiology (EAPC); Tj ETQq1 1 0.784314 rgBT /Overlock <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1736-1752.	1.8	9
70	Dutch Outcome in Implantable Cardioverterâ€Defibrillator Therapy: Implantable Cardioverterâ€Defibrillatorâ€Related Complications in a Contemporary Primary Prevention Cohort. <i>Journal of the American Heart Association</i> , 2021, 10, e018063.	3.7	8
71	Predicting defibrillator benefit in patients with cardiac resynchronization therapy: A competing risk study. <i>Heart Rhythm</i> , 2019, 16, 1057-1064.	0.7	7
72	Incremental Value of an Insertable Cardiac Monitor in Patients with Hypertrophic Cardiomyopathy with Low or Intermediate Risk for Sudden Cardiac Death. <i>Cardiology</i> , 2021, 146, 207-212.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Long-term mortality risk in patients with an implantable cardioverter-defibrillator: Influence of heart rate and QRS duration. <i>International Journal of Cardiology</i> , 2014, 175, 560-564.	1.7	6
74	Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2017, 119, 1414-1420.	1.6	6
75	Efficacy and safety of transvenous lead extraction using a liberal combined superior and femoral approach. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 62, 239-248.	1.3	6
76	Comprehensive multicomponent cardiac rehabilitation in cardiac implantable electronic devices recipients: a consensus document from the European Association of Preventive Cardiology (EAPC); Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Europace</i> , 2021, 23, 1336-1337o.	1.7	5
77	Application of the heart failure meta-score to predict prognosis in patients with cardiac resynchronization defibrillators. <i>International Journal of Cardiology</i> , 2021, 330, 73-79.	1.7	5
78	Defibrillation threshold testing at implantation: can we predict the patient with a high defibrillation threshold?. <i>Europace</i> , 2010, 12, 309-310.	1.7	4
79	Nationwide Longitudinal Follow-Up of Riata Leads Under Advisory at 3 Annual Screenings. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 887-893.	3.2	4
80	Frequency of Need for Antitachycardia or Antibradycardia Pacing or Cardiac Resynchronization Therapy in Patients With a Single-Chamber Implantable Cardioverter-Defibrillator. <i>American Journal of Cardiology</i> , 2018, 122, 2068-2074.	1.6	4
81	Evaluation of recurrent ventricular tachyarrhythmias in patients who survived out-of-hospital cardiac arrest due to ventricular fibrillation: eligibility for subcutaneous implantable defibrillator therapy. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 317-323.	1.3	4
82	Sex-specific differences in outcome and risk stratification of ventricular arrhythmias in implantable cardioverter defibrillator patients. <i>ESC Heart Failure</i> , 2021, 8, 3726-3736.	3.1	4
83	Accuracy of atrial fibrillation detection by an insertable cardiac monitor in patients undergoing catheter ablation: Results of the <sc>BioVAD</sc> study. <i>Annals of Noninvasive Electrocardiology</i> , 2022, 27, e12960.	1.1	4
84	Usefulness of a standard 12-lead electrocardiogram to predict the eligibility for a subcutaneous defibrillator. <i>Journal of Electrocardiology</i> , 2019, 55, 123-127.	0.9	3
85	Anger and long-term mortality and ventricular arrhythmias in patients with a first-time implantable cardioverter-defibrillator: data from the MIDAS study. <i>Europace</i> , 2020, 22, 1054-1061.	1.7	3
86	Predicting Early Mortality Among Implantable Defibrillator Patients Treated With Cardiac Resynchronization Therapy. <i>Journal of Cardiac Failure</i> , 2019, 25, 812-818.	1.7	2
87	Reassessment of clinical variables in cardiac resynchronization defibrillator patients at the time of first replacement: Death after replacement of CRT (DARC) score. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1687-1694.	1.7	2
88	Implantable loop recorders in patients with heart disease: comparison between patients with and without syncope. <i>Open Heart</i> , 2021, 8, e001748.	2.3	2
89	The value of remote care in the reduction of healthcare utilization in implantable cardioverter-defibrillator patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, , .	1.2	2
90	The Effect of Elapsed Time from Myocardial Infarction on Mortality and Major Adverse Cardiac and Cerebrovascular Events in ICD Patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1448-1455.	1.2	1

#	ARTICLE	IF	CITATIONS
91	Questioning the preference for dual- vs. single-chamber implantable defibrillator in primary prevention implantable cardioverter-defibrillator recipients. <i>Europace</i> , 2017, 19, 1416-1417.	1.7	1
92	EHRA certification: a 15-year journey of attesting excellence in arrhythmia healthcare. <i>Europace</i> , 2022, 24, 175-178.	1.7	1
93	Predictors for early mortality and arrhythmic events in patients with cardiac resynchronization therapy with defibrillator: A two center cohort study. <i>Cardiology Journal</i> , 2020, 26, 711-716.	1.2	1
94	Emerging electromagnetic interferences between implantable cardioverter-defibrillators and left ventricular assist devices: Authors'™ reply. <i>Europace</i> , 2020, 22, 1911-1912.	1.7	1
95	Anger and mortality following ICD implantation: Authors'™ reply. <i>Europace</i> , 2021, 23, 650-650.	1.7	1
96	High Cerebrovascular Thromboembolic Event Rate Long after Unsuccessful Catheter Ablation for Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2294.	0.5	1
97	Pocket hematoma after pacemaker or defibrillator surgery: Direct oral anticoagulants versus vitamin K antagonists. <i>IJC Heart and Vasculature</i> , 2022, 39, 101005.	1.1	1
98	Patients with congenital heart disease: how to determine the eligibility for implantation of a subcutaneous implantable defibrillator?. <i>Europace</i> , 2015, 17, 1003-1004.	1.7	0